Evidence map›Paper›PMID 34101090›Full record

ReviewNeuromolecular medicine2022

Contemporary RNA Therapeutics for Glioblastoma.

Kaitlyn Melnick, Farhad Dastmalchi, Duane Mitchell, Maryam Rahman, Elias J Sayour

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuromolecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04573140 (A Phase I/II Study of RNA-lipid Particle), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04573140 phase1recruitingnot on this map

A Phase I/II Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM), and Recurrent/Progressive Medulloblastoma (MB)

TypeinterventionalSponsorUniversity of FloridaRan2021 to 2029Enrolled28ConditionsAdult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant GliomaArmsAutologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kaitlyn MelnickDepartment of Neurosurgery, University of Florida, Gainesville, FL, USA. Kaitlyn.melnick@neurosurgery.ufl.edu.
Farhad DastmalchiDepartment of Neurosurgery, University of Florida, Gainesville, FL, USA.
Duane MitchellDepartment of Neurosurgery, University of Florida, Gainesville, FL, USA.
Maryam Rahman *Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Elias J Sayour *Department of Neurosurgery, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-5309-3197

Funding

Overcoming the blood-brain barrier with nanoparticle vaccines against gliomasR37CA251978 · NCI · UNIVERSITY OF FLORIDA · PI Elias Sayour · 2021 to 2026
$3.4M
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)R01CA175517 · NCI · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A., SAMPSON, JOHN H. · 2015 to 2020
$3.1M
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade GliomasR01CA195563 · NCI · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A., PACKER, ROGER · 2015 to 2019
$2.8M
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in GlioblastomaK08NS099484 · NINDS · UNIVERSITY OF FLORIDA · PI RAHMAN, MARYAM · 2017 to 2021
$1.1M
Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting GlioblastomaK08CA199224 · NCI · UNIVERSITY OF FLORIDA · PI SAYOUR, ELIAS · 2016 to 2020
$791k
NCI NIH HHS K08 CA199224NCI NIH HHS R01 CA175517NCI NIH HHS R01 CA195563NCI NIH HHS R37 CA251978NINDS NIH HHS K08 NS099484
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM. RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability. This review will focus on utilization of RNA dendritic cell vaccines and RNA nanoparticle therapies in the treatment of GBM. RNA-pulsed dendritic cell vaccines have been shown to be safe in a small phase I clinical trial and RNA-loaded nanoparticle vaccines will soon be underway in GBM patients (NCT04573140).

Indexed as

Brain NeoplasmsCancer VaccinesGlioblastomaAdultClinical Trials, Phase I as TopicDendritic CellsHumansImmunotherapyRNACancer VaccinesRNADendritic cellsGlioblastomaImmunotherapyNanoparticlesRNAVaccine

Identifiers

PMID34101090
PMCPMC8186014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.